NCT06302985 Atomized Inhalation ICG for Treatment of Congenital Lung Malformations
| NCT ID | NCT06302985 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jiexiong Feng |
| Condition | Pulmonary Sequestration |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2050-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2024-03-01 with a primary completion date of 2050-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate the safety and effectiveness of preoperative aerosol inhalation ICG solution for thoracoscopic accurate resection of congenital lung malformations in children.
Eligibility Criteria
Inclusion Criteria: * children with congenital lung malformations diagnosed by CT or MRI scan Exclusion Criteria: * 1\. ages \<3 months and \>14 years 2. complicated other life-threatening disease; 3. complicated severely pulmonary infection
Contact & Investigator
Tianqi Zhu, MD
PRINCIPAL INVESTIGATOR
Tongji Hospital
Frequently Asked Questions
Who can join the NCT06302985 clinical trial?
This trial is open to participants of all sexes, aged 3 Months or older, up to 14 Years, studying Pulmonary Sequestration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06302985 currently recruiting?
Yes, NCT06302985 is actively recruiting participants. Contact the research team at zhutianqi84@163.com for enrollment information.
Where is the NCT06302985 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT06302985 clinical trial?
NCT06302985 is sponsored by Jiexiong Feng. The principal investigator is Tianqi Zhu, MD at Tongji Hospital. The trial plans to enroll 50 participants.